Market Access Impact (EU5) [Cancer Pain]
Market Access Impact (EU5) [Cancer Pain]

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk
Market Access Impact (EU5) [Cancer Pain]

Market barriers may not be the only reason doctors don’t prescribe your brand

Market barriers only affect 12% of cancer pain prescriptions in the EU5 countries. Most brands gain market share because of them, but for some brands, perception may be an even bigger problem. And over 10% of doctors either wouldn’t prescribe these brands, or simply haven’t heard of them at all.

Find out how doctors see your brand, and whether market barriers are dragging your market share down, in Market Access Impact: Cancer Pain (EU5).

Based on a survey of 150 medical oncologists, the report covers 7 major therapies from Kyowa Kirin, Teva, Takeda, and Mundipharma/Napp. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Not your market? Click here to see the US report

Request sample pages

Top Takeaways

Most brands gain. While every brand wins and loses share because of barriers, 5 of the 7 surveyed brands see a net gain, albeit very small for some brands.

No one barrier is to blame. Most of the 7 barriers covered in the report affect the same amount of prescriptions.

Barrier impact is small. Over 45-65% of surveyed doctors experience only one barrier with any given brand, but for some brands that climbs to 3 barriers.

Some brands are hit harder by certain barriers. Learn which brand doctors have the most trouble reimbursing, which three products lose out due to patient type recommendations, and more.

Do the brands have a perception problem? Up to 30% of doctors either wouldn’t consider prescribing these brands, or haven’t heard of them at all.

Insight into 7 Major Cancer Pain Treatments

Abstral (fentanyl sublingual; Kyowa Kirin)

Actiq (fentanyl transmucosal; Teva)
Effentora (fentanyl buccal; Teva)
Instanyl (fentanyl intranasal; Takeda)
Oxycontin (oxycodone CII; Mundipharma/Napp)
OxyNorm (oxycodone IR; Mundipharma/Napp)
PecFent (fentanyl intranasal; Kyowa Kirin)

Exploring Market Access Barriers

Market Access Impact: Cancer Pain (EU5) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical oncologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with NSCLC in total in the last month

We conducted the survey between September 1-12, 2017

Money Back Guarantee!
At FirstWord, we stand behind our reports. If you’re not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Additional Details

Publisher: FirstWord Pharma
Reference: 
Number of Pages: 0
Report Format: PDF
Publisher Information:
Table Of Contents for Market Access Impact (EU5) [Cancer Pain] [Report Updated: 01-09-2017]

- 1. What are market barriers?
- 2. About this report
- 3. About the survey
- 4. Brands included in the survey
- 5. Executive summary
How to Buy...

Market Access Impact (EU5) [Cancer Pain] [Report Updated: 01-09-2017]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/150153

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: 
Job Title: 
Your Email: 
Your Contact Phone: 
Company Name: 
Address: 
Post/Zip Code: 
Country: 
P.O. Number: 
Any Other Instructions: 

Pricing Options: (please tick one)
○ &sh;&##36;5145 | Single User Price
○ &sh;&##36;7725 | Global License Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: 

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.